Dividend Alert: Dec 15, 2016 will mean $0.16 dividends for Mesa Laboratories, Inc. (NASDAQ:MLAB) shareholders.

Dividend Alert: Dec 15, 2016 will mean $0.16 dividends for Mesa Laboratories, Inc. (NASDAQ:MLAB) shareholders.

Mesa Laboratories, Inc. (NASDAQ:MLAB) is expected to pay $0.16 on Dec 15, 2016. The indicated annual dividend is $0.64. Shareholders owning the stock before Nov 28, 2016 will be eligible to receive the payout. Based on Mesa Laboratories, Inc.’s current price of $131.82, the dividend is 0.12%. This dividend’s record date is Nov 30, 2016 and the announcement date is Oct 5, 2016. The stock decreased 2.21% or $2.98 on November 25, hitting $131.82. About 4,425 shares traded hands. Mesa Laboratories, Inc. (NASDAQ:MLAB) has risen 36.15% since April 25, 2016 and is uptrending. It has outperformed by 30.14% the S&P500.

Mesa Laboratories, Inc. is focused primarily on quality control services and products. The company has a market cap of $474.31 million. The Firm operates through four divisions: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. It has a 44.11 P/E ratio. The Instruments Division designs, makes and markets quality control instruments and disposable products.

Insitutional Activity: The institutional sentiment decreased to 1.46 in 2016 Q2. Its down 0.68, from 2.14 in 2016Q1. The ratio dived, as 5 funds sold all Mesa Laboratories, Inc. shares owned while 16 reduced positions. 15 funds bought stakes while 30 increased positions. They now own 1.99 million shares or 2.18% less from 2.04 million shares in 2016Q1.
Bnp Paribas Arbitrage holds 0% or 117 shares in its portfolio. Glenmede Trust Na last reported 1,175 shares in the company. Quantbot Techs Ltd Partnership has 55 shares for 0% of their US portfolio. State Street accumulated 44,000 shares or 0% of the stock. The New York-based Jpmorgan Chase & has invested 0% in Mesa Laboratories, Inc. (NASDAQ:MLAB). Rocky Mountain Advisers has 500 shares for 0.33% of their US portfolio. Bankshares Of America De owns 204 shares or 0% of their US portfolio. Schwab Charles Management Incorporated owns 4,800 shares or 0% of their US portfolio. Tower Rech Cap Llc (Trc) last reported 745 shares in the company. Vanguard Gp has 130,267 shares for 0% of their US portfolio. Metropolitan Life owns 2,256 shares or 0% of their US portfolio. Rhumbline Advisers has 3,114 shares for 0% of their US portfolio. Blackrock Advsr Limited Liability Co has 0% invested in the company for 1,412 shares. Savings Bank Of Montreal Can accumulated 1,251 shares or 0% of the stock. Rice Hall James And Limited last reported 0.19% of its portfolio in the stock.

Insider Transactions: Since June 6, 2016, the stock had 0 buys, and 4 selling transactions for $1.28 million net activity. CAMPBELL H STUART sold $476,080 worth of stock or 4,000 shares. Adriance Glenn E sold $335,220 worth of Mesa Laboratories, Inc. (NASDAQ:MLAB) on Monday, June 6. 1,000 shares were sold by Sakys John, worth $127,140 on Tuesday, November 15.

More news for Mesa Laboratories, Inc. (NASDAQ:MLAB) were recently published by: Marketwatch.com, which released: “Mesa Laboratories downgraded to neutral from buy at Sidoti & Co.” on April 21, 2011. Quotes.Wsj.com‘s article titled: “News Mesa Laboratories Inc.MLAB” and published on February 11, 2011 is yet another important article.

MLAB Company Profile

Mesa Laboratories, Inc., incorporated on March 26, 1982, is focused primarily on quality control services and products. The Firm operates through four divisions: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, makes and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. The Company’s Biological Indicators Division provides testing services, along with the manufacturing and marketing of biological indicators and distribution of chemical indicators used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. The Company’s Continuous Monitoring Division designs, develops and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity and differential pressure in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and various other laboratory and industrial environments. The Company’s Cold Chain Division provides parameter (primarily temperature) monitoring of products in a cold chain, consulting services, such as compliance monitoring, packaging development and validation or mapping of transport and storage containers, and thermal packaging products, such as coolers, boxes, insulation materials and phase-change products to control temperature during transport.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment